Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBM “transparency” lawsuit

Executive Summary

The Pharmaceutical Care Management Association files suit June 29 in Washington, D.C. federal court to block enforcement of the District's "AccessRx Act of 2004," enacted in May. The law requires full disclosure of PBMs' fees and financial terms between PBMs and drug companies, designates PBMs as fiduciaries, and requires pass through of all payments and discounts from manufacturers. The association contends that D.C.'s law violates the Commerce and Takings Clauses of the U.S. Constitution and that it is preempted by the federal Employee Retirement Income Security Act. A Maine federal court judge granted a preliminary injunction in March against a similar provision in that state (1"The Pink Sheet" March 15, 2004, p. 17)....

You may also be interested in...



PBM Regulation In Maine Blocked By Federal Court; ERISA Preempts State

Maine's attempt to regulate the pharmacy benefit management industry is preempted by the Employee Retirement Income Security Act, Maine federal court Judge John Woodcock ruled March 9

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel